Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunocompromised Host Clear all
Completed Phase 1Phase 2 Interventional

Anidulafungin in Treating Immunocompromised Children With Neutropenia

NCT00068471
View directory record Official record
Conditions
Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

NCT07050732
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
Biological · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

NCT04530786
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine in Pediatric Transplant Subjects

NCT00133510
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Subviron Influenza vaccine (Fluzone)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

NCT00390780
View directory record Official record
Conditions
HIV Infections
Interventions
miconazole Lauriad, Clotrimazole
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2013 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

NCT00002015
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
3 Months to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

NCT02352389
View directory record Official record
Conditions
Influenza, Human
Interventions
Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
14
States / cities
Antioch, California • Daly City, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

NCT04364178
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander, MD
Other
Eligibility
1 Month to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Netivudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jul 22, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects

NCT05102461
View directory record Official record
Conditions
Diarrhea Caused by Drug, Dysbiosis
Interventions
Florajen Digestion Supplementation, Placebo Supplementation
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

ZOSTAVAX® in Renal Transplant Patients

NCT01137669
View directory record Official record
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002339
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

NCT00002132
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Itraconazole, Fluconazole
Drug
Lead sponsor
Janssen Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

NCT00998803
View directory record Official record
Conditions
Influenza Virus
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jul 22, 2026, 10:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT06258551
View directory record Official record
Conditions
Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

NCT05366322
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 22, 2026, 10:22 AM EDT